Meeting
2014 ASCO Annual Meeting
Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types.
Authors
Ignace Vergote
Department of Oncology,University Hospitals Leuven and Katholieke Universiteit Leuven, Leuven, Belgium
Ignace Vergote , Douglas Wilmot Ball , Masatoshi Kudo , Pallavi Sachdev , Mark Matijevic , Tadashi Kadowaki , Yasuhiro Funahashi , Keith Flaherty
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Clinical Trial Registration Number
NCT00784303,NCT01111461,NCT01136967,NCT00946153,NCT01433991,
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11061)
DOI
10.1200/jco.2014.32.15_suppl.11061
Abstract #
11061
Poster Bd #
343
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
A phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC).
First Author: Martin Schlumberger
Poster
2017 Gastrointestinal Cancers Symposium
Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).
First Author: Masafumi Ikeda
Poster
2016 ASCO Annual Meeting
Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: Final analysis results.
First Author: Shunji Takahashi
Poster
2015 ASCO Annual Meeting
Combination of everolimus and sorafenib in the treatment of thyroid cancer: Update on phase II study.
First Author: Eric Jeffrey Sherman